Celldex therapeutics stock

Celldex Therapeutics is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat  24 Feb 2020 Celldex Therapeutics Inc. [NASDAQ: CLDX] closed the trading session at $3.07 on 02/21/20. The day's price range saw the stock hit a low of 

Feb 21, 2020 · Online Stock Comparison - Compare Celldex Therapeutics, Inc. (CLDX) to four other stocks with NASDAQ.com's stock comparison tool. This Is (Another) Opportunity To Buy ADMA Biologics (ADMA ... 1 day ago · A Look At Celldex Therapeutics (NASDAQ:CLDX) With the previous 100-day trading volume average of 256856 shares, Celldex Therapeutics (CLDX) recorded a trading volume of 260380 shares, as the stock started the trading session at the value of $1.65, in the end touching the price of $1.73 after jumping by 4.85%. CLDX: Celldex Therapeutics Inc - Stock Price, Quote and ... Get Celldex Therapeutics Inc (CLDX:NASDAQ) real-time stock quotes, news and financial information from CNBC. Celldex Therapeutics Stock Quote. CLDX - Stock Price, News ...

Celldex Therapeutics, Inc. (CLDX) Stock Analysis & News ...

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic CELLDEX THERAPEUTICS, INC. : Stock Price | MarketScreener Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the … CLDX Interactive Stock Chart | Celldex Therapeutics, Inc ...

Taking a look at the performance of Celldex Therapeutics, Inc. stock, a stockholder knows that the weekly performance for this stock is valued at 32.90%, resulting in a performance for the month at 34.06%.. Therefore, the stated figure shows a four-month performance of 44.13%, bringing the 6-month working result to 30.08% and YTD performance of 37.67%.

CLDX Stock Quote - Celldex Therapeutics, Inc. Price - Nasdaq Stock quote for Celldex Therapeutics, Inc. Common Stock (CLDX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. CLDX Stock Quote - Celldex Therapeutics, Inc. Stock Price ... Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to …

Historical daily share price chart and data for Celldex Therapeutics since 1990 adjusted for splits. The latest closing stock price for Celldex Therapeutics as of March 03, 2020 is 2.48.. The all-time high Celldex Therapeutics stock closing price was 3014.70 on March 06, 2000.; The Celldex Therapeutics 52-week high stock price is 5.47, which is 120.6% above the current share price.

Celldex Therapeutics Stock Quote. CLDX - Stock Price, News ...

View today's stock price, news and analysis for Celldex Therapeutics Inc. (CLDX) . Barron's also provides information on historical stock ratings, target prices, 

Celldex Therapeutics (CLDX) Stock Up on Q2 Results. By Kaya Yurieff. Aug 9, 2016 1:45 PM EDT. MARKETS. Celldex Therapeutics (CLDX) Is Strong On High Volume Today. By TheStreet Wire. Stock Screener - Stock Research Reports and Ratings ... Stock-At-A-Glance. Below is a summary of the major fundamental and technical factors we consider when determining our overall recommendation of CLDX shares. Celldex Therapeutics Inc. Stock Price (CLDX) | Barron's View today's stock price, news and analysis for Celldex Therapeutics Inc. (CLDX). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation

CLDX Earnings Date, Forecast and Report (Celldex Therapeutics) Celldex Therapeutics (NASDAQ:CLDX) Earnings Information. Celldex Therapeutics last released its quarterly earnings results on March 26th, 2020. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.26.